Worldwide COVID-19 testing continues to ramp up consistently, predominantly using RT-PCR as the “gold standard”. However, more sensitive testing applications are now being introduced. We are proud to announce that Helix has received emergency use authorization (EUA) from the FDA for COVID-19 testing using next generation sequencing (NGS) with iSWAB-Microbiome as the collection method. Using NGS for COVID testing allows for greater in-depth interrogation of samples, leading to more accurate testing results and flexibility for the use of high-throughput automation.
Ultimately, what matters most about COVID-19 testing is that the viral RNA remains stable from point of collection to processing. If not transported with cold chain methods and processed within 48-72 hours, a positive sample that has been sitting in traditional VTM/MTM could end up yielding false-negative results due to RNA degradation. Our non-toxic iSWAB-Microbiome sample collection technology has proven to maintain viral RNA integrity for weeks after collection while also showing complete compatibility with multiple extraction chemistries, downstream applications, and automation platforms making it a perfect fit for COVID-19 sample collection and transport.
Read More Here: Helix COVID-19 NGS Test – EUA Summary
Mawi DNA Technologies Partners with GenoBank.io To Tokenize Our Groundbreaking…...
October 14, 2024 – We are thrilled to announce that Mawi DNA Technologies has officially partnered with READ MORE
Mawi DNA Partners with Tempus AI and Tally Health™ to…...
October 7, 2024 – Customers frequently ask what swabs are compatible with our iSWAB® non-invasive sample collection technology. Although most swab types can be used with our system, incl...
READ MORESolena Ag and Mawi DNA Partner to Revolutionize Soil Health…...
January 4, 2024 – Solena Ag, a leader in soil health insights for sustainable agriculture, and Mawi DNA Technologies (Mawi DNA), a pioneer in high-integrity sample collection and storage, today anno...
READ MORE
